Method and composition for hyperthermally treating cells
A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.
1. A method providing diagnosis or therapy to a patient in need thereof, the method comprising administering to a patient a composition comprising a targeting agent- and/or antitumor-antibody-labeled nanoparticle and/or quantum dot, where the nanoparticle and/or quantum dot forms a targeting agent- and/or antibody-labeled nanoparticle and/or quantum dot-exosome complex, exposing the circulatory system of the patient to an energy source wherein the nanoparticle and/or quantum dot responds by expanding thus generating an acoustic signal, measuring the acoustic signal and relating the measured signal to a temperature of the nanoparticle and/or quantum dot exosome complex, and controlling the temperature of the nanoparticle and/or quantum dot exosome complex from about 39° C. to about 58° C. based on the acoustic signal to hyperthermally damage the exosome.
2. The method of claim 1 providing diagnosis of a pathology in the patient by quantitating the amount or concentration of the nanoparticle and/or quantum dot exosome complex, detecting a relatively increased amount or concentration of the nanoparticle and/or quantum dot exosome complex in the patient in need thereof compared to a control individual, and diagnosing the pathology based on the detected amount or concentration.
3. The method of claim 1 providing and assessing therapy to a pathology in the patient by quantitating the amount or concentration of the nanoparticle and/or quantum dot exosome complex, detecting a relatively decreased amount or concentration of the nanoparticle and/or quantum dot exosome complex in the patient in need thereof after thermal therapy compared to the patient in need thereof prior to thermal therapy, and assessing therapy based on the detected amount or concentration.
4. The method of claim 1 where the exosomes are the products of infectious cells or malignant cells.
5. The method of claim 1 where quantitating is by flow cytometry.
6. The method of claim 1 applying thermal therapy to a solid tissue using a targeting agent localizing the nanoparticle and/or quantum dot to the solid tissue.
7. The method of claim 1 applying thermal therapy to a fluid tissue using a targeting agent localizing the nanoparticle and/or quantum dot to the fluid tissue.
8. The method of claim 7 wherein the fluid tissue is blood and the exosomes are circulating in the vasculature.
9. The method of claim 1 optionally repeated a plurality of times on a patient having a relatively increased concentration of circulating exosomes originating from malignant cells, the method used to treat increased aggressiveness of the malignant cells.
10. The method of claim 1 further comprising infusing into the patient a population of the patient's exosomes that were subjected to in vitro co-culture with a population of the patient's defensive cells selected from the group consisting of antigen-presenting cells (APC), dendritic cells, macrophages, phagocytes, and combinations thereof.
11. The method of claim 1 where the nanoparticles and/or quantum dots are associated and/or coated with a thermosensitive polymer to deliver compounds that are anti-tumor or anti-cancer agents.
12. The method of claim 11 where the polymer is chitosan or chitin, and where the compounds are antineoplastic agents or anti-infectious agents.
13. The method of claim 1 where the nanoparticles and/or quantum dots are associated and/or coated with an agent to enhance biocompatibility.
14. A method providing diagnosis or therapy to a to a patient in need of neurodegenerative diagnosis or therapy, the method comprising administering to the patient a composition comprising an anti-beta-amyloid protein targeting agent-labeled nanoparticle and/or quantum dot of between 1 nm-5 nm in size, where the nanoparticle and/or quantum dot forms a targeting agent- and/or antibody: labeled nanoparticle and/or quantum dot exosome complex, exposing the circulatory system of the patient to an energy source wherein the nanoparticle and/or quantum dot responds by expanding thus generating an acoustic signal, measuring the acoustic signal and relating the measured signal to a temperature of the nanoparticle and/or quantum dot exosome complex, and controlling the temperature of the nanoparticle and/or quantum dot exosome complex from about 39° C. to about 58° C. based on the acoustic signal to hyperthermally damage the exosome and an associated beta-amyloid protein.
15. The method of claim 14 where the patent has a neurodegenerative disease of the eye, Alzheimer's disease, or Parkinson's disease.
16. The method of claim 14 where the anti-beta amyloid protein antibody is crenezumab.